Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
04 September 2023 - 7:48PM
Update on the combination of Novozymes and Chr. Hansen: Chinese
merger approval granted, supporting the path to completion
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES,
CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION
WHERE SUCH ACTION WOULD BE UNLAWFUL.
SEPTEMBER 4, 2023
On December 12, 2022, Novozymes A/S ("Novozymes") and Chr.
Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and
Chr. Hansen propose to combine and create a leading global
biosolutions partner by way of a statutory merger of the two
companies. Reference is made to Chr. Hansen's company announcement
no. 13 of December 12, 2022.
The Chinese State Administration for Market Regulation (SAMR)
has now unconditionally approved the statutory merger of Novozymes
and Chr. Hansen. The approval by SAMR was a condition to completion
of the combination. The completion of the combination remains
subject to the satisfaction of an additional number of conditions
set out in the merger plan, including certain additional regulatory
approvals. Completion of the combination is expected to occur in
the fourth quarter of 2023 or the first quarter of 2024.
Further details on the expected timing for the completion of the
combination will be published as relevant.
Transaction website For additional information,
visit www.power-with-biology.com or
https://www.chr-hansen.com/en/investors/proposed-merger/
About Chr. Hansen Chr. Hansen is a global,
differentiated bioscience company that develops natural ingredient
solutions for the food, nutritional, pharmaceutical and
agricultural industries. At Chr. Hansen, we are strongly positioned
to drive positive change through microbial solutions. We have
worked for over 145 years to enable sustainable agriculture, better
food and healthier living for more people around the world. Our
microbial and fermentation technology platforms, including our
broad and relevant collection of around 50,000 microbial strains,
have game-changing potential. Matching customer needs and global
trends, we continue to unlock the power of good bacteria to respond
to global challenges such as food waste, global health and the
overuse of antibiotics and pesticides. As the world’s most
sustainable food ingredients company, we touch the lives of more
than 1 billion people every day. Driven by our legacy of innovation
and curiosity to pioneer science, our purpose – To grow a better
world. Naturally. – is at the heart of everything we do.
About Novozymes Novozymes is the world leader
in biological solutions. Together with customers, partners, and the
global community, we improve industrial performance while
preserving the planet's resources and helping build better lives.
As the world's largest provider of enzyme and microbial
technologies, our bioinnovation enables higher agricultural yields,
low-temperature washing, energy-efficient production, renewable
fuel, and many other benefits that we rely on today and in the
future. We call it Rethink Tomorrow.
Please see attachment.
Contact information
Novozymes: Investor Relations Tobias Cornelius
Björklund +45 3077 8682 tobb@novozymes.com
Press Relations Lina Danstrup +45 3077 0552
lind@novozymes.com
Chr. Hansen: Investor Relations Anders Mohr
Christensen +45 2515 2364 dkamc@chr-hansen.com
Press Relations Sanne Seyer-Hansen +45 6038
6207 dksash@chr-hansen.com
- 2023_Chinese merger approval granted
Chr Hansen (TG:51C)
Historical Stock Chart
From Nov 2024 to Dec 2024
Chr Hansen (TG:51C)
Historical Stock Chart
From Dec 2023 to Dec 2024
